Lead Director, Chair of Corporate Governance & Compensation Committee, Audit Committee, Risk Committee
Michael Auerbach is the founder and managing member of Subversive Capital LLC, a firm committed to investing in transformative companies whose missions challenge the status quo and necessitate nuanced regulatory strategies for success. Pioneering in emerging industries, Subversive Capital specializes in both early and late-stage investments. Since November 2021, Auerbach has also assumed the role of managing member at Subversive Capital Advisor LLC, a SEC-registered investment advisor. Mr. Auerbach brings a wealth of experience to his roles. He serves as Partner and Head of Intelligence at DGA Group and previously held a longstanding executive position at Albright Stonebridge Group, a global consultancy founded by former Secretary of State Madeleine Albright and a foundational partner to DGA. In addition to his directorship with Canaccord Genuity Group Inc., Mr. Auerbach also is a director at Atai Life Sciences NV., a clinical-stage biopharmaceutical firm listed on Nasdaq, since June 2021. Previously, he served on the board of directors of Tilray Brands Inc., the pioneering Nasdaq-listed global cannabis company, from February 2018 to May 2021. Beyond his corporate engagements, Mr. Auerbach is actively involved in various philanthropic endeavors. He serves on the boards of the Theodore C. Sorensen Center for International Peace and Justice, the KiDS Board of NYU’s Hassenfeld Children’s Hospital, Next for Autism (producer of Night of Too Many Stars), Finding a Cure for Epilepsy (FACES), and the Sophie Gerson Healthy Youth Foundation. Mr. Auerbach holds a Master’s degree in International Relations from Columbia University’s School for International and Public Affairs (‘05) and a Bachelor’s degree in Critical Theory from the New School for Social Research (‘97). In addition to Canaccord Genuity Group Inc., Mr. Auerbach is a director of the following public companies: Atai Life Sciences NV.
